HDAC9 and hematologic disorder: To date, the US Food and Drug Administration has approved four pan-HDAC inhibitors for the treatment of various cancers, especially hematological malignancies such as cutaneous T cell lymphoma [8], peripheral T cell lymphoma [9], and multiple myeloma [10].